Results 101 to 110 of about 10,096 (205)

MYCNamplification confers enhanced folate dependence and methotrexate sensitivity in neuroblastoma

Oncotarget, 2015
MYCN amplification occurs in 20% of neuroblastomas and is strongly related to poor clinical outcome. We have identified folate-mediated one-carbon metabolism as highly upregulated in neuroblastoma tumors with MYCN amplification and have validated this finding experimentally by showing that MYCN amplified neuroblastoma cell lines have a higher ...
Lau, DT, Flemming, CL, Gherardi, S, Perini, G, Oberthuer, A, Fischer, M, Juraeva, D, Brors, B, Xue, C, Norris, MD, Marshall, GM, Haber, M, Fletcher, JI, Ashton, LJ   +13 more
openaire   +4 more sources

High-Level MYCN-Amplified RB1-Proficient Retinoblastoma Tumors Retain Distinct Molecular Signatures [PDF]

, 2022
Khashayar Roohollahi, Yvonne de Jong, Saskia E. van Mil, Armida W. M. Fabius, Annette C. Moll, Josephine C. Dorsman   +5 more
openalex   +1 more source

Critical Role for GAB2 in Neuroblastoma Pathogenesis through the Promotion of SHP2/MYCN Cooperation

Cell Reports, 2017
Growing evidence suggests a major role for Src-homology-2-domain-containing phosphatase 2 (SHP2/PTPN11) in MYCN-driven high-risk neuroblastoma, although biologic confirmation and a plausible mechanism for this contribution are lacking.
Xiaoling Zhang, Zhiwei Dong, Cheng Zhang, Choong Yong Ung, Shuning He, Ting Tao, Andre M. Oliveira, Alexander Meves, Baoan Ji, A. Thomas Look, Hu Li, Benjamin G. Neel, Shizhen Zhu   +12 more
doaj   +1 more source

Mouse models of pediatric high-grade gliomas with MYCN amplification reveal intratumoral heterogeneity and lineage signatures. [PDF]

Nat Commun, 2023
Schoof M, Godbole S, Albert TK, Dottermusch M, Walter C, Ballast A, Qin N, Olivera MB, Göbel C, Neyazi S, Holdhof D, Kresbach C, Peter LS, Epplen GD, Thaden V, Spohn M, Blattner-Johnson M, Modemann F, Mynarek M, Rutkowski S, Sill M, Varghese J, Afflerbach AK, Eckhardt A, Münter D, Verma A, Struve N, Jones DTW, Remke M, Neumann JE, Kerl K, Schüller U.   +31 more
europepmc   +1 more source

Targeting Ornithine Decarboxylase Impairs Development of MYCN -Amplified Neuroblastoma [PDF]

, 2009
Robert J. Rounbehler, Weimin Li, Mark A. Hall, Chunying Yang, Mohammad Fallahi, John L. Cleveland   +5 more
openalex   +1 more source

A Chemo-Genomic Approach Identifies Diverse Epigenetic Therapeutic Vulnerabilities in MYCN-Amplified Neuroblastoma

, 2021
Aleksandar Krstić, Anja Konietzny, Melinda Halász, Peter Cain, Udo Oppermann, Walter Kölch, David J. Duffy   +6 more
openalex   +1 more source

Intraventricular mass in a 49‐year‐old male

Brain Pathology, Volume 36, Issue 1, January 2026.
Connor R. Zuraski, Donald P. Pizzo, Jessica D. Schulte, Vanessa S. Goodwill   +3 more
wiley   +1 more source

High Genomic Instability Predicts Survival in Metastatic High-Risk Neuroblastoma

Neoplasia: An International Journal for Oncology Research, 2012
We aimed to identify novel molecular prognostic markers to better predict relapse risk estimate for children with high-risk (HR) metastatic neuroblastoma (NB). We performed genome- and/or transcriptome-wide analyses of 129 stage 4 HR NBs.
Sara Stigliani, Simona Coco, Stefano Moretti, Andrè Oberthuer, Mattias Fischer, Jessica Theissen, Fabio Gallox, Alberto Garavent, Frank Berthold, Stefano Bonassi, Gian Paolo Tonini, Paola Scaruffi   +11 more
doaj   +1 more source

A Novel Mechanism of 17-AAG Therapeutic Efficacy on HSP90 Inhibition in MYCN-Amplified Neuroblastoma Cells

, 2021
Reine Hanna, Jad Abdallah, Thamara J. Abouantoun   +2 more
openalex   +1 more source

MYCN amplification predicts poor outcome for patients with supratentorial primitive neuroectodermal tumors of the central nervous system [PDF]

, 2014
Marco Gessi, André O. von Bueren, András Treszl, Anja zur Mühlen, Wolfgang Hartmann, Monika Warmuth‐Metz, Stefan Rutkowski, Torsten Pietsch   +7 more
openalex   +1 more source